OPRX

OptimizeRx Corporation (OPRX) | Rumor.io

OptimizeRx

OPRX

Attention (50-day avg)0%

Attention rank (50-day avg)#4,025

Bullish sentiment (50-day avg)100%

Price to earnings ratio31.8

Market capitalization147.1M

Earnings per share0.25

Dividend yield (TTM)—

Revenue (annual)109.4M

Net income (annual)5.1M

Social

What share of all stock conversation is about OPRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

May 12

OptimizeRx Corporation's (OPRX) Q1 2026 revenue was $19.8M, a 10% YoY decline, but adjusted EBITDA increased from $1.5M to $3.3M.
The company's profitability improved, with a 75% YoY increase in adjusted EPS to $0.14, and a reduction in net loss to $0.5M.
OPRX updated its FY 2026 guidance, expecting revenue of $95M to $100M and adjusted EBITDA of $21M to $25M, with a new $35M credit agreement reducing interest rates and saving $1.5M annually.

Generated by AI

Sentiment

Of the messages about OPRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	84.21% +3.21
Bearish	—	0%	0%	15.79% -3.21

Bullish· Mar 12

$OPRX broke out of a bullish descending wedge, indicating a potential price increase.
The company's strong Q4 earnings, with revenue up 14% YoY and Adjusted EBITDA +53%, suggest a solid growth momentum.
$OPRX has a promising outlook for 2025, with a revenue forecast of $100M+ and a new CEO in place, fueling momentum and potentially leading to another leg up.

Bearish· Mar 12

$OPRX is experiencing significant losses, with a decline from 6.20 to 5.70.
The company's financial situation is precarious, with a cash burn rate of $20 million per year and a high debt-to-equity ratio of 64%.
The stock has formed a double top pattern in the past 5 months, which could indicate a reversal in price, and has lost significant volume.

Generated by AI

Topics

Of the messages about OPRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	87.02%
Analysts	—	0%	0%	3.44%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	2.67%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	6.87%

Mar 12

$OPRX reports Q4 revenue $32.317M, consensus $30.36M, with EPS 30c beating consensus 27c.
The company expects to generate at least $100M in revenue and at least $12M in Adjusted EBITDA in FY25.
OptimizeRx achieved strong Q4 earnings, with revenue up 14% YoY, and gross margin at 68%, with 48 DAAP deals in 2024, doubling last year's performance.

Generated by AI

Community

Of the messages about OPRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	28.57%	17.63%
Newcomers	—	100%	71.43%	82.37%

Regulars· Mar 9

OptimizeRx has announced a multi-year agreement with a top hub services provider to accelerate patient access, which may have a positive impact on the company's business.
The company has reported its fourth quarter and full year 2022 financial results, with earnings beating estimates and a press release issued on the matter.
Analysts have revised their price targets for OptimizeRx, with B Riley lowering its target to $28, Lake Street Capital to $18, RBC to $18, and Stifel Nicolaus to $16.

Newcomers· Aug 10

The Q2 EPS for OptimizeRx Corporation ($OPRX) was reported as $0.04, missing the Capital IQ consensus of $0.09, and revenue of $14.0 mln also missed the consensus of $16.5 mln.
The company's FY22 revenue guidance is $62-68 mln, which is below the Capital IQ consensus of $74.2 mln.
OptimizeRx Corporation's stock price target was cut to $37 from $56 at B. Riley.

Generated by AI

News

Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?

6d agoYahoo Finance

OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network

The move gives life sciences advertisers a more streamlined way to bring specialized healthcare audiences into their broader digital media strategies.

7d agoYahoo Finance

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook (NASDAQ:OPRX)

12d agoSeeking Alpha

OptimizeRx appoints Troy Sarich as company advisor

27d agoInvesting.com

OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor

Experienced pharmaceutical and healthcare executive joins advisory board to help accelerate innovation and strengthen life sciences marketing technologyWALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Troy Sarich as a Company advisor. Sarich

28d agoYahoo! Finance Canada

OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript

Detailed price information for Optimizerx Corp (OPRX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about OPRX also mention

#	Name	Attention
1	Doximity Inc. Class A Common StockDOCS	0%0
2	GoodRx Holdings, Inc. Class A Common StockGDRX	0%new
3	Fulgent Genetics, Inc.FLGT	0%0
4	Hagerty, Inc.HGTY	0%new
5	Smith Douglas Homes CorporationSDHC	0%0
6	eXp World Holdings, Inc.EXPI	0%0
7	908 Devices Inc.MASS	0%0
8	Transcontinental Realty Investors, Inc.TCI	0%0
9	Digital Turbine, Inc.APPS	0%+0
10	TTEC Holdings, Inc.TTEC	0%0

OptimizeRx Corporation

Healthcare
Health Information Services

OptimizeRx Corporation is a healthcare technology company that helps life sciences organizations connect with healthcare professionals and patients through digital engagement tools. OptimizeRx Corporation’s current offerings include digital health messaging, electronic health record workflow solutions, financial messaging, patient education, brand messaging, and patient engagement services. Its platform is designed to deliver timely clinical, educational, and access-related information at the point of care, supporting communication across pharmaceutical manufacturers, providers, and patients. The company operates within the healthcare information services and digital health market, where it plays a role in improving how treatment information and support resources are shared in clinical settings. Founded in 2006 and headquartered in Waltham, Massachusetts, OptimizeRx Corporation focuses on technology-enabled solutions for the healthcare communications ecosystem.

Website

Location

260 Charles Street

Waltham, MA, 02453

United States

Social

What share of all stock conversation is about OPRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

May 12

OptimizeRx Corporation's (OPRX) Q1 2026 revenue was $19.8M, a 10% YoY decline, but adjusted EBITDA increased from $1.5M to $3.3M.
The company's profitability improved, with a 75% YoY increase in adjusted EPS to $0.14, and a reduction in net loss to $0.5M.
OPRX updated its FY 2026 guidance, expecting revenue of $95M to $100M and adjusted EBITDA of $21M to $25M, with a new $35M credit agreement reducing interest rates and saving $1.5M annually.

Generated by AI

Sentiment

Of the messages about OPRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	84.21% +3.21
Bearish	—	0%	0%	15.79% -3.21

Bullish· Mar 12

$OPRX broke out of a bullish descending wedge, indicating a potential price increase.
The company's strong Q4 earnings, with revenue up 14% YoY and Adjusted EBITDA +53%, suggest a solid growth momentum.
$OPRX has a promising outlook for 2025, with a revenue forecast of $100M+ and a new CEO in place, fueling momentum and potentially leading to another leg up.

Bearish· Mar 12

$OPRX is experiencing significant losses, with a decline from 6.20 to 5.70.
The company's financial situation is precarious, with a cash burn rate of $20 million per year and a high debt-to-equity ratio of 64%.
The stock has formed a double top pattern in the past 5 months, which could indicate a reversal in price, and has lost significant volume.

Generated by AI

Topics

Of the messages about OPRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	87.02%
Analysts	—	0%	0%	3.44%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	2.67%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	6.87%

Mar 12

$OPRX reports Q4 revenue $32.317M, consensus $30.36M, with EPS 30c beating consensus 27c.
The company expects to generate at least $100M in revenue and at least $12M in Adjusted EBITDA in FY25.
OptimizeRx achieved strong Q4 earnings, with revenue up 14% YoY, and gross margin at 68%, with 48 DAAP deals in 2024, doubling last year's performance.

Generated by AI

Community

Of the messages about OPRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	28.57%	17.63%
Newcomers	—	100%	71.43%	82.37%

Regulars· Mar 9

OptimizeRx has announced a multi-year agreement with a top hub services provider to accelerate patient access, which may have a positive impact on the company's business.
The company has reported its fourth quarter and full year 2022 financial results, with earnings beating estimates and a press release issued on the matter.
Analysts have revised their price targets for OptimizeRx, with B Riley lowering its target to $28, Lake Street Capital to $18, RBC to $18, and Stifel Nicolaus to $16.

Newcomers· Aug 10

The Q2 EPS for OptimizeRx Corporation ($OPRX) was reported as $0.04, missing the Capital IQ consensus of $0.09, and revenue of $14.0 mln also missed the consensus of $16.5 mln.
The company's FY22 revenue guidance is $62-68 mln, which is below the Capital IQ consensus of $74.2 mln.
OptimizeRx Corporation's stock price target was cut to $37 from $56 at B. Riley.

Generated by AI

OptimizeRx

Social

May 12

Bullish· Mar 12

Bearish· Mar 12

Mar 12

Regulars· Mar 9

Newcomers· Aug 10

Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?

OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook (NASDAQ:OPRX)

OptimizeRx appoints Troy Sarich as company advisor

OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor

OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript

Also Discussed

OptimizeRx Corporation

Company Information

Location

Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?

OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook (NASDAQ:OPRX)

OptimizeRx appoints Troy Sarich as company advisor

OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor

OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript

Also Discussed

Social

May 12

Bullish· Mar 12

Bearish· Mar 12

Mar 12

Regulars· Mar 9

Newcomers· Aug 10